Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study

2020 ◽  
Vol 95 ◽  
pp. 106385 ◽  
Author(s):  
Aaron D. Goldberg ◽  
Ehab Atallah ◽  
David Rizzieri ◽  
Roland B. Walter ◽  
Ki-Young Chung ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Acute Lymphoblastic Leukemia ◽  
Phase I ◽  
Myeloid Leukemia ◽  
Phase I Study ◽  
Lymphoblastic Leukemia ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Acute Myeloid ◽  
Antibody Drug

scholarly journals An Anti–CLL-1 Antibody–Drug Conjugate for the Treatment of Acute Myeloid Leukemia

2018 ◽  
Vol 25 (4) ◽  
pp. 1358-1368 ◽  
Author(s):  
Bing Zheng ◽  
Shang-Fan Yu ◽  
Geoffrey del Rosario ◽  
Steven R. Leong ◽  
Genee Y. Lee ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Acute Myeloid ◽  
Antibody Drug

scholarly journals CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

2018 ◽  
Vol 2 (14) ◽  
pp. 1738-1749 ◽  
Author(s):  
Ying-Ping Jiang ◽  
Bob Y. Liu ◽  
Quan Zheng ◽  
Swapna Panuganti ◽  
Ruoying Chen ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Stem Cell ◽  
Myeloid Leukemia ◽  
Leukemic Stem Cell ◽  
Cell Targeting ◽  
Antibody Drug Conjugate ◽  
Drug Conjugate ◽  
Key Points ◽  
Acute Myeloid ◽  
Antibody Drug

Key Points CLL1-ADC targets both AML blasts and LSCs. Unlike CD33-ADC, CLL1-ADC does not affect normal HSCs.

Sign in / Sign up

Export Citation Format

Share Document